Hologic

HOLX

Market cap $14.9B

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.

HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.

Hologic's breast health innovations, AI breakthroughs and leadership moves signal optimism ahead despite macro headwinds.

Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.

In the closing of the recent trading day, Hologic (HOLX) stood at $67.91, denoting a +1.3% move from the preceding trading day.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #Bacterial--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The company also announced that the assays obtained CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (IVDR). These highly sensitive molecular tests are designed to rapidly detect the most common bacterial pathogens res.

Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.